Effectiveness of a nursing support program for patients with recurrent ovarian cancer receiving pegylated liposomal doxorubicin (Caelyx®/Doxil®)

N. Grenier, V. Lebel, M. Gill, T. Mullen, K. Mitchinson, K. Sebborn, Jean-François Pouliot

Abstract


Pegylated liposomal doxorubicin (PLD) has become the preferred alternative for ovarian cancer patients who have failed platinumbased therapy, but side effects, such as palmar-plantar erythrodysesthesia (PPE), may lead to sub-optimal drug exposure and treatment discontinuation. A prospective Canadian multicentre open-label study evaluated the effects of a nurse-administered education and support program on treatment adherence and tolerability in 112 women with recurrent ovarian cancer. Subjects received an average of four four-week PLD cycles, the recommended number of courses required to evaluate the efficacy from PLD. Side effects were common, but 75% of patients were able to complete > 3 cycles and 59% completed > 4 cycles of PLD chemotherapy. With proactive nursing intervention, the incidence of PLD-associated grade three-four toxicities such as PPE and mucositis was substantially decreased. Nursing intervention may allow more patients to receive chemotherapy on schedule, thus reproducing the conditions of the clinical study in which the efficacy of the drug has been established.


Full Text:

PDF

References


Campos, S.M., Penson, R.T., Mays, A.R., Berkowitz, R.S., Fuller,

A.F., Goodman, A., et al. (2001). The clinical utility of liposomal

doxorubicin in recurrent ovarian cancer. Gynecol Oncol, 81, 206-

Canadian Cancer Society/National Cancer Institute of Canada.

(2005). Canadian Cancer Statistics 2005. Toronto, Canada.

Retrieved December 19, 2005, from www.cancer.ca

Gabizon, A., & Martin, F. (1997). Polyethylene glycol-coated

(pegylated) liposomal doxorubicin. Rationale for use in solid

tumours. Drugs, 54(Suppl. 4), 15-21.

Gabizon, A.A. (2001). Pegylated liposomal doxorubicin:

Metamorphosis of an old drug into a new form of chemotherapy.

Cancer Invest, 19, 424-436.

Gordon, A.N., Granai, C.O., Rose, P.G., Hainsworth, J., Lopez, A.,

Weissman, C., et al. (2000). Phase II study of liposomal

doxorubicin in platinum- and paclitaxel-refractory epithelial

ovarian cancer. J Clin Oncol, 18, 3093-3100.

Gordon, A.N., Fleagle, J.T., Guthrie, D., Parkin, D.E., Gore, M.E., &

Lacave, A.J. (2001). Recurrent epithelial ovarian carcinoma: A

randomized phase III study of pegylated liposomal doxorubicin

versus topotecan. J Clin Oncol, 19, 3312-3322.

Gordon, A.N., & Butler, J. (2003). Chemotherapeutic management of

advanced ovarian cancer. Semin Oncol Nurs, 19(3, Suppl. 1), 3-

Gordon, A.N., Tonda, M., Sun, S., & Rackoff, W., on behalf of the

Doxil Study 30-39 investigators. (2004). Long-term survival

advantage for women treated with pegylated liposomal

doxorubicin compared with topotecan in a phase 3 randomized

study of recurrent and refractory epithelial ovarian cancer.

Gynecologic Oncol, 95, 1-8.

Muggia, F.M., Hainsworth, J.D., Jeffers, S., Miller, P., Groshen, S.,

Tan, M., et al. (1997). Phase II study of liposomal doxorubicin in

refractory ovarian cancer: antitumor activity and toxicity

modification by liposomal encapsulation. J Clin Oncol, 15, 987-

Nair, M.G., Hickok, J.T., Roscoe, J.A., & Morrow, G.R. (2000).

Sources of information used by patients to learn about

chemotherapy side effects. J Cancer Educ, 15, 19-22.

Ozols, R.F. (2005). Update on the management of ovarian cancer.

Cancer J, 8(Suppl. 1), S22-S30.

Parmar, M.K., Ledermann, J.A., Colombo, N., du Bois, A., Delaloye,

J.F., Kristensen, G.B., et al. (2003). Paclitaxel plus platinum-based

chemotherapy versus conventional platinum-based chemotherapy

in women with relapsed ovarian cancer: The ICON4/AGO-OVAR-

2 trial. Lancet, 361, 2099-2106.

Rose, P.G., Maxson, J.H., Fusco, N., Mossbruger, K., & Rodriguez,

M. (2001). Liposomal doxorubicin in ovarian, peritoneal, and

tubal carcinoma: A retrospective comparative study of singleagent

dosages. Gynecol Oncol, 82, 323-328.

National Cancer Institute. Surveillance, Epidemiology, and End

Results (SEER) database. Retrieved January 10, 2006, from

http://seer.cancer.gov/statfacts/html/ovary.html.


Refbacks

  • There are currently no refbacks.